Pharmabiz
 

Pfizer, IBM collaborate to develop remote monitoring solutions to transform Parkinson’s disease care

New YorkMonday, April 11, 2016, 18:00 Hrs  [IST]

Pfizer Inc. and IBM announced a first-of-its-kind research collaboration to develop innovative remote monitoring solutions aimed at transforming how clinicians deliver care to patients suffering from Parkinson’s disease. The experimental approach will rely on a system of sensors, mobile devices, and machine learning to provide real-time, around-the-clock disease symptom information to clinicians and researchers. The ultimate goal is to obtain a better understanding of a patient’s disease progression and medication response to help inform treatment decisions and clinical trial design, while also speeding the development of new therapeutic options.

Parkinson’s disease in particular requires ongoing adjustment to medication depending on the progression of the disease and response of the patient. The collaboration seeks to create a holistic view of a patient’s well-being by seeking to accurately measure a variety of health indicators, including motor function, dyskinesia, cognition, sleep and daily activities such as grooming, dressing and eating. Insights from these data could help clinicians understand the effect of a patient’s medication as the disease progresses, enabling them to help optimize the patient’s treatment regimen as needed. Data generated through the system could also arm researchers with the insights and real-world evidence needed to help accelerate potential new and better therapies.

According to the World Health Organization, neurological disorders including Parkinson’s disease, Alzheimer’s disease, stroke, multiple sclerosis and epilepsy impact almost one billion families around the worldi and account for 12 percent of total deaths globally. Many diseases of the brain, spine, and nerves are progressive conditions that get worse over time and can create uncontrolled movement, impair the ability to think, and cause other debilitating symptoms impacting the patient’s quality of life. Approximately 60,000 Americans are diagnosed with Parkinson’s disease each year according to the Parkinson’s Disease Foundation, and an estimated seven to 10 million people suffer from the disease globally.

“We have an opportunity to potentially redefine how we think about patient outcomes and 24/7 monitoring, by combining Pfizer’s scientific, medical and regulatory expertise with IBM’s ability to integrate and interpret complex data in innovative ways,” said Mikael Dolsten, M.D., Ph.D., president of Pfizer Worldwide Research and Development. “The key to our success will be to deliver a reliable, scalable system of measurement and analysis that would help inform our clinical programs across important areas of unmet medical need, potentially accelerating the drug development and regulatory approval processes and helping us to get better therapies to patients, faster.”

“With the proliferation of digital health information, one area that remains elusive is the collection of real-time physiological data to support disease management,” said Arvind Krishna, senior vice president and director of IBM Research. “We are testing ways to create a system that passively collects data with little to no burden on the patient, and to provide doctors and researchers with objective, real-time insights that we believe could fundamentally change the way patients are monitored and treated.”

The two companies project that the system will move into initial clinical testing quickly. Pfizer and IBM will convene an external advisory board of patient groups, advocacy organiations, clinicians, and neuroscientists for guidance on the use of technology, medical devices, data management, and research protocols, and to ensure the needs of patients guide the program.

This project marks a significant milestone in IBM’s work to advance Internet of Things (IoT) technologies in healthcare. Emory University Hospital is creating an instrumented ICU using IBM's streaming analytics technology to advance predictive medicine for critical patients in the ICU. The new system will enable clinicians to acquire, analyse and correlate medical data at a volume and velocity that was never before possible. Neonatal intensive care specialists at The University of Ontario Institute of Technology are relying on the same software to analyse more than 1,000 pieces of unique information per second flowing from sensors and equipment monitoring premature babies, helping caregivers spot the onset of sepsis infections up to 24 hours earlier. And, Medtronic is working with IBM Watson Health to create a cognitive app designed to analyse real-time data from Medtronic devices to help detect important patterns and trends for people with diabetes.

 
[Close]